Cargando…
Bladder (ICRU) dose point does not predict urinary acute toxicity in adjuvant isolated vaginal vault high-dose-rate brachytherapy for intermediate-risk endometrial cancer
PURPOSE: High-dose-rate brachytherapy (HDR-BT) alone is an adjuvant treatment option for stage I intermediaterisk endometrial cancer after complete surgical resection. The aim of this study was to determine the value of the dose reported to ICRU bladder point in predicting acute urinary toxicity. On...
Autores principales: | Sapienza, Lucas Gomes, Aiza, Antonio, Gomes, Maria José Leite, Chen, Michael Jenwei, Pellizzon, Antonio Cassio de Assis, Mansur, David B., Baiocchi, Glauco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663209/ https://www.ncbi.nlm.nih.gov/pubmed/26622241 http://dx.doi.org/10.5114/jcb.2015.54952 |
Ejemplares similares
-
Volumetric (3D) bladder dose parameters are more reproducible than point (2D) dose parameters in vaginal vault high-dose-rate brachytherapy
por: Sapienza, Lucas Gomes, et al.
Publicado: (2016) -
Salvage high-dose-rate interstitial brachytherapy for locally
recurrent rectal cancer
por: Pellizzon, Antônio Cássio Assis
Publicado: (2016) -
Pain relief procedures before high-dose-rate brachytherapy for non-surgical treatment of cervix cancer
por: Pellizzon, Antonio Cássio Assis
Publicado: (2018) -
Evidence and clinical outcomes of adult soft tissue sarcomas of the extremities treated with adjuvant high-dose-rate brachytherapy – a literature review
por: Pellizzon, Antonio Cássio Assis
Publicado: (2014) -
Effects of bladder distension on dose distribution of vaginal vault brachytherapy in patients with endometrial cancer
por: Guler, Ozan C., et al.
Publicado: (2014)